Show simple item record

 
dc.contributorHospital General de Granollers
dc.contributor.authorMussa, Marco
dc.contributor.authorMartínez Pérez-Crespo, Pedro María
dc.contributor.authorSousa-Dominguez, Adrián
dc.contributor.authorGoikoetxea-Aguirre, Ane Josune
dc.contributor.authorLópez-Cortés, Luis Eduardo
dc.contributor.authorRetamar-Gentil, Pilar
dc.date.accessioned2022-07-25T08:43:48Z
dc.date.available2022-07-25T08:43:48Z
dc.date.issued2022-06-30
dc.identifier.citationMussa M, Martínez Pérez-Crespo PM, Lopez-Cortes LE, Retamar-Gentil P, Sousa-Dominguez A, Goikoetxea-Aguirre AJ, et al. Risk Factors and Predictive Score for Bacteremic Biliary Tract Infections Due to Enterococcus faecalis and Enterococcus faecium: a Multicenter Cohort Study from the PROBAC Project. Microbiol Spectr. 2022 Jun 30:e0005122.
dc.identifier.urihttps://hdl.handle.net/11351/7915
dc.descriptionEnterococcus spp; Biliary tract infection; Bloodstream infection
dc.description.abstractBiliary-tract bloodstream infections (BT-BSI) caused by Enterococcus faecalis and E. faecium are associated with inappropriate empirical treatment and worse outcomes compared to other etiologies. The objective of this study was to investigate the risk factors for enterococcal BT-BSI. Patients with BT-BSI from the PROBAC cohort, including consecutive patients with BSI in 26 Spanish hospitals between October 2016 and March 2017, were selected; episodes caused by E. faecalis or E. faecium and other causes were compared. Independent predictors for enterococci were identified by logistic regression, and a predictive score was developed. Eight hundred fifty episodes of BT-BSI were included; 73 (8.5%) were due to target Enterococcus spp. (48 [66%] were E. faecium and 25 [34%] E. faecalis). By multivariate analysis, the variables independently associated with Enterococcus spp. were (OR; 95% confidence interval): cholangiocarcinoma (4.48;1.32 to 15.25), hospital acquisition (3.58;2.11 to 6.07), use of carbapenems in the previous month (3.35;1.45 to 7.78), biliary prosthesis (2.19;1.24 to 3.90), and moderate or severe chronic kidney disease (1.55;1.07 to 2.26). The AUC of the model was 0.74 [95% CI0.67 to 0.80]. A score was developed, with 7, 6, 5, 4, and 2 points for these variables, respectively, with a negative predictive value of 95% for a score ≤ 6. A model, including cholangiocarcinoma, biliary prosthesis, hospital acquisition, previous carbapenems, and chronic kidney disease showed moderate prediction ability for enterococcal BT-BSI. Although the score will need to be validated, this information may be useful for deciding empirical therapy in biliary tract infections when bacteremia is suspected. IMPORTANCE Biliary tract infections are frequent, and a significant cause of morbidity and mortality. Bacteremia is common in these infections, particularly in the elderly and patients with cancer. Inappropriate empirical treatment has been associated with increased risk of mortality in bacteremic cholangitis, and the probability of receiving inactive empirical treatment is higher in episodes caused by enterococci. This is because many of the antimicrobial agents recommended in guidelines for biliary tract infections lack activity against these organisms. To the best of our knowledge, this is the first study analyzing the predictive factors for enterococcal BT-BSI and deriving a predictive score.
dc.language.isoeng
dc.publisherAmerican Society for Microbiology
dc.relation.ispartofseriesMicrobiology Spectrum;
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectEnterococs
dc.subjectConductes biliars - Infeccions
dc.subjectBacterièmia
dc.subject.meshEnterococcus
dc.titleRisk Factors and Predictive Score for Bacteremic Biliary Tract Infections Due to Enterococcus faecalis and Enterococcus faecium: a Multicenter Cohort Study from the PROBAC Project
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1128/spectrum.00051-22
dc.subject.decsEnterococcus
dc.relation.publishversionhttps://doi.org/10.1128/spectrum.00051-22
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.authoraffiliation[Mussa M] Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Infectious Diseases Unit, Milan, Italy. UGC Enfermedades Infecciosas y Microbiología, Hospital Universitario Virgen Macarena, Sevilla, Spain. Departamento de Medicina, Universidad de Sevilla/IBiS/CSIC, Sevilla, Spain. [Martínez Pérez-Crespo PM] Centro de Investigación Biomédica en Red en Enfermedades Infecciosas (CIBERINFEC), Sevilla, Spain. Hospital Universitario de Valme, Sevilla, Spain. [Lopez-Cortes LE] UGC Enfermedades Infecciosas y Microbiología, Hospital Universitario Virgen Macarena, Sevilla, Spain. Centro de Investigación Biomédica en Red en Enfermedades Infecciosas (CIBERINFEC), Sevilla, Spain. [Retamar-Gentil P] UGC Enfermedades Infecciosas y Microbiología, Hospital Universitario Virgen Macarena, Sevilla, Spain. Departamento de Medicina, Universidad de Sevilla/IBiS/CSIC, Sevilla, Spain. Centro de Investigación Biomédica en Red en Enfermedades Infecciosas (CIBERINFEC), Sevilla, Spain. [Sousa-Dominguez A] Hospital Universitario de Vigo, Vigo, Spain. [Goikoetxea-Aguirre AJ] Hospital de Cruces, Bilbao, Spain. [Cuquet-Pedragosa J] Hospital General Granollers, Granollers, Spain
dc.identifier.pmid35771010
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record